Literature DB >> 6345255

Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis.

M Colombo, R Cambieri, M G Rumi, G Ronchi, E Del Ninno, R De Franchis.   

Abstract

To assess the prevalence and clinical significance of delta-infection in chronic hepatitis B surface antigen carriers, we examined 326 liver biopsies from 192 retrospectively selected carriers by immunofluorescence. Delta antigen was detected in 102 specimens from 50 carriers (26.2%) with peak prevalence in patients with active cirrhosis (51.5%) and generally in close association with progressive liver disease (94%). The antigen was located in the nuclei of 2%-50% of the hepatocytes, without any disease-specific pattern of fluorescence. Patients with intrahepatic delta-antigen, however, had more severe liver disease than those without it. Histologic follow-up of 101 cases showed that the rates of worsening of the liver disease were similar in delta-antigen-positive and in delta-antigen-negative patients. It is concluded that delta-superinfection does play a role in worsening the histologic picture of hepatitis B surface antigen-positive chronic active hepatitis, possibly by liver injury induced acutely at the moment of infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345255

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

1.  Interaction between HDV and HBV infection in HBsAg-chronic carriers.

Authors:  E Sagnelli; F M Felaco; M Rapicetta; T Stroffolini; A Petruzziello; T Annella; P Chionne; G Pasquale; P Filippini; P Peinetti
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

2.  Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus.

Authors:  Cheng Huang; Shin C Chang; Hui-Chin Yang; Chung-Liang Chien; Ming-Fu Chang
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

3.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles.

Authors:  R Nisini; M Paroli; D Accapezzato; F Bonino; F Rosina; T Santantonio; F Sallusto; A Amoroso; M Houghton; V Barnaba
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Nuclear export signal-interacting protein forms complexes with lamin A/C-Nups to mediate the CRM1-independent nuclear export of large hepatitis delta antigen.

Authors:  Cheng Huang; Jia-Yin Jiang; Shin C Chang; Yeou-Guang Tsay; Mei-Ru Chen; Ming-Fu Chang
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

5.  Hepatitis delta infections.

Authors:  K G Nicholson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

Review 6.  Natural history of the HBsAg carrier.

Authors:  M G Anderson; I M Murray-Lyon
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

7.  The delta agent comes of age.

Authors:  H C Thomas
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

8.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

9.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

Review 10.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.